

## **Supplementary Information**

### **Insights into the Protective Effect of Pycnogenol Against Methotrexate-Induced Toxicity: *in silico* and *in vivo* study**

Faten Al-Abkal<sup>1</sup>, Basel A. Abdel-Wahab<sup>2</sup>, Hanaa F. Abd El-Kareem<sup>3</sup>, Yasser M. Moustafa<sup>1,4</sup>, Dina M. Khodeer<sup>1,\*</sup>

## Supplement for regression analysis


### 1- Biochemical analysis:

#### a) Serum biomarkers:

i. Liver function: activities of ALT, AST enzymes

ii. Kidney function: level of urea and creatinine

iii. Heart function: level of troponin and activities of CK and CK-MB enzymes




**Figure S1.** Regression trendline showing the relationship between increasing Pycnogenol levels (10, 20, and 30 mg Kg<sup>-1</sup>) with various serum biomarkers.


**B) Tissue markers: (heart, liver and kidney)**

i. Inflammatory biomarkers: NF- $\kappa$ B and TNF- $\alpha$  level


ii. Oxidative stress markers: MDA, ATP and GSH levels, activities of SOD and CAT enzymes



**Figure S2.** Regression trendline showing the relationship between increasing Pycnogenol levels (10, 20, and 30 mg Kg-1) and various heart biomarkers.



**Figure S3.** Regression trendline showing the relationship between increasing Pycnogenol levels (10, 20, and 30 mg Kg<sup>-1</sup>) and various liver biomarkers.



**Figure S4.** Regression trendline showing the relationship between increasing Pycnogenol levels (10, 20, and 30 mg Kg<sup>-1</sup>) and various kidney biomarkers.